Company Overview of Immune Targeting Systems (ITS) Limited
Immune Targeting Systems (ITS) Limited develops synthetic vaccines for mutating viruses and cancer. The company develops FP-01, a synthetic vaccine against various seasonal and pandemic influenza strains. It also offers vaccines for the prevention and treatment of life-threatening viral infections, including HIV/AIDS and hepatitis-company, as well as FIV (cat AIDS). The company was incorporated in 1992 and is based in London, United Kingdom.
London Bioscience Innovation Centre
2 Royal College Street
London, NW1 0NH
Founded in 1992
Key Executives for Immune Targeting Systems (ITS) Limited
Executive Chairman and Chief Executive Officer
Research & Development Director
Compensation as of Fiscal Year 2014.
Immune Targeting Systems (ITS) Limited Key Developments
Vaxin Inc. and Immune Targeting Systems (ITS) Limited Announce Board Changes
Feb 17 15
Vaxin Inc. announced that it has entered into a definitive agreement to acquire Immune Targeting Systems (ITS) Ltd. Dr. David Drutz, (Executive Chairman and Chief Medical Officer, DARA BioSciences) will remain Chairman of the combined company. Other board members include Brigadier General (ret.) Klaus Schafer, MD, MPH, Philip Hodges (Redmont Capital), Florent Gros (Novartis Venture Fund), Philippe Pouletty, MD (Truffle Capital), Marten Steen, MD, PhD (HealthCap) and Bill Enright (Vaxin CEO).
Immune Targeting Systems to Develop New T Cell Vaccine
Aug 18 14
Immune Targeting Systems has been developing an exciting new T cell vaccine designed to protect humans from all strains of seasonal and pandemic influenza A. To determine the effectiveness of Flunisyn ITS produced its own live influenza challenge agent derived from the recently circulating Influenza A/California/2009 virus. This challenge virus, manufactured in compliance with the high level of quality and characterization required by the U.S. FDA and other Regulatory Agencies, has a much better infectivity profile than reported for similar challenge viruses. Whilst the main purpose in developing its own challenge virus was to advance the development of Flunisyn and to further understand the natural course of influenza illness, ITS wants to make the virus available to enable and support the development of new antiviral drugs and vaccines. Immune Targeting Systems announced an asset purchase agreement with WCCT Global for ITS' proprietary developed challenge strain. Through this partnership, WCCTG has become the only commercial company offering sponsors the ability to do large scale influenza challenge studies in the United States. The Experimental Human Viral Challenge Model has become widely accepted as an alternative to traditional early stage field trials to show the efficacy of antiviral and vaccine therapies. The WCCTG facility in Costa Mesa, California, has been completely reconfigured to provide private rooms, separate ventilation and other standard containment provisions to accommodate this valuable research model and ensure the safety and comfort of the volunteers and staff.
Immune Targeting Systems (ITS) Limited Presents at BioEquity Europe 2013, May-23-2013 09:00 AM
May 19 13
Immune Targeting Systems (ITS) Limited Presents at BioEquity Europe 2013, May-23-2013 09:00 AM. Venue: Sheraton Stockholm, Stockholm, Sweden.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 17, 2015